Certara, Inc. (NASDAQ:CERT) Given Average Rating of “Hold” by Analysts

Shares of Certara, Inc. (NASDAQ:CERT) have been given a consensus recommendation of “Hold” by the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.85.

A number of analysts have commented on CERT shares. Barclays reduced their price target on Certara from $8.00 to $6.50 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Stephens cut their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Weiss Ratings reissued a “sell (e+)” rating on shares of Certara in a report on Friday, May 29th. BMO Capital Markets decreased their target price on shares of Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a research note on Tuesday, May 12th. Finally, Robert W. Baird lowered their price target on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a report on Tuesday, May 12th.

Certara Trading Up 3.1%

Shares of Certara stock opened at $7.28 on Friday. Certara has a 1-year low of $4.45 and a 1-year high of $13.88. The company’s fifty day simple moving average is $5.76 and its 200-day simple moving average is $6.71. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.88 and a quick ratio of 1.88. The stock has a market capitalization of $1.13 billion, a PE ratio of -72.80 and a beta of 1.46.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $106.92 million during the quarter, compared to analysts’ expectations of $106.13 million. Certara had a positive return on equity of 3.52% and a negative net margin of 3.60%.The company’s revenue for the quarter was up .8% on a year-over-year basis. During the same quarter last year, the company earned $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. As a group, equities analysts anticipate that Certara will post 0.24 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of CERT. Wasatch Advisors LP grew its holdings in Certara by 28.6% during the 3rd quarter. Wasatch Advisors LP now owns 17,398,337 shares of the company’s stock valued at $212,608,000 after buying an additional 3,865,455 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Certara by 2.1% during the first quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock worth $48,806,000 after acquiring an additional 175,024 shares during the last quarter. Deerfield Management Company L.P. boosted its position in shares of Certara by 71.7% during the third quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after acquiring an additional 2,813,438 shares during the last quarter. Ameriprise Financial Inc. grew its stake in Certara by 27.1% during the second quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after acquiring an additional 1,165,064 shares in the last quarter. Finally, State Street Corp grew its stake in Certara by 2.2% during the fourth quarter. State Street Corp now owns 3,918,784 shares of the company’s stock valued at $34,524,000 after acquiring an additional 83,698 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.